KAER Biotherapeutics is a preclinical aerosol drug delivery company addressing the needs of respiratory ailments in clinics and hospitals. KAER is primarily focused on the provision of surfactant aerosol therapy for patients in respiratory distress related to the absence of sufficient active lung surfactant. These patients include prematurely born infants whose lungs are not producing sufficient low surface tension surfactant to enable their airways to fully open and support adequate respiratory function. Neonatal Respiratory Distress Syndrome, NRDS, is the major cause of mortality in prematurely born neonates. At any age, but especially in the elderly, insults to the lungs and body can induce acute respiratory distress. Acute respiratory distress syndrome, ARDS, results from abnormal surfactant production and inflammation-induced degradation of surfactant. When this is the result of a direct insult to the lungs, such as pneumonia or smoke inhalation, it is denoted acute lung injury, ALI. ALI can rapidly deteriorate into ARDS. There are no approved drugs for patients with ARDS. Despite the best life support, 40% of these patients die. KAER developed patented enabling aerosol generation, processing and delivery technology to address these needs. KAER’s SUPRAER technology aerosolizes liquids containing the surfactant or other active pharmaceutical agent and delivers them as concentrated pure fine particle solid-phase aerosols suitable for deep lung deposition. SUPRAER is differentiated by its ability to aerosolize viscous fluids and suspensions of high molecular weight agents. High masses of fine particle therapeutic aerosols therapies can be rapidly administered at clinically relevant doses. KAER is seeking partners to facilitate the rapid implementation of this the aerosol delivery technology for the treatment of respiratory distress, IPF, hospital acquired pneumonia, TB, NSCLC and other debilitating lung diseases.